Length‐independent telomere damage drives post‐mitotic cardiomyocyte senescence
Rhys Anderson,Anthony Lagnado,Damien Maggiorani,Anna Walaszczyk,Emily Dookun,James Chapman,Jodie Birch,Hanna Salmonowicz,Mikolaj Ogrodnik,Diana Jurk,Carole Proctor,Clara Correia‐Melo,Stella Victorelli,Edward Fielder,Rolando Berlinguer‐Palmini,Andrew Owens,Laura C Greaves,Kathy L Kolsky,Angelo Parini,Victorine Douin‐Echinard,Nathan K LeBrasseur,Helen M Arthur,Simon Tual‐Chalot,Marissa J Schafer,Carolyn M Roos,Jordan D Miller,Neil Robertson,Jelena Mann,Peter D Adams,Tamara Tchkonia,James L Kirkland,Jeanne Mialet‐Perez,Gavin D Richardson,João F Passos
DOI: https://doi.org/10.15252/embj.2018100492
2019-02-08
The EMBO Journal
Abstract:Ageing is the biggest risk factor for cardiovascular disease. Cellular senescence, a process driven in part by telomere shortening, has been implicated in age-related tissue dysfunction. Here, we address the question of how senescence is induced in rarely dividing/post-mitotic cardiomyocytes and investigate whether clearance of senescent cells attenuates age-related cardiac dysfunction. During ageing, human and murine cardiomyocytes acquire a senescent-like phenotype characterised by persistent DNA damage at telomere regions that can be driven by mitochondrial dysfunction and crucially can occur independently of cell division and telomere length. Length-independent telomere damage in cardiomyocytes activates the classical senescence-inducing pathways, p21CIP and p16INK4a, and results in a non-canonical senescence-associated secretory phenotype, which is pro-fibrotic and pro-hypertrophic. Pharmacological or genetic clearance of senescent cells in mice alleviates detrimental features of cardiac ageing, including myocardial hypertrophy and fibrosis. Our data describe a mechanism by which senescence can occur and contribute to age-related myocardial dysfunction and in the wider setting to ageing in post-mitotic tissues.